Half-dose photodynamic therapy is Effective in treating chro
A Study was conducted to compare the efficacy and safety between half-dose photodynamic therapy (PDT) and eplerenone for treating chronic central serous chorioretinopathy (cCSC).

Eligible patients were randomized at a 1:1 ratio to receive either indocyanine green angiography-guided half-dose PDT or oral eplerenone for 12 weeks. Both anatomical and functional outcomes were evaluated at 3 months after the start of treatment.

--A total of 107 patients were randomly assigned to receive either half-dose PDT (n=53) or eplerenone treatment (n=54).

--13 patients (3 in the PDT group and 10 in the eplerenone group) did not adhere to the study protocol.

--At the 3-month evaluation visit, 78% of patients in the PDT group had complete resolution of SRF, compared to only 17% of patients in the eplerenone group.

--Mean best-corrected visual acuity in Early Treatment of Diabetic Retinopathy Study letters at the evaluation visit was 83.7±10.8 and 82.8±9.0 in the PDT and eplerenone groups, respectively.

--In addition, mean retinal sensitivity on microperimetry was 25.4±3.4 dB and 23.9±4.0 dB in the PDT and eplerenone groups, respectively.

--Finally, mean vision-related quality of life scores were 87.2±8.5 and 83.8±12.1 in the PDT and eplerenone groups, respectively.

--3 patients in the PDT group (6%) experienced adverse events during the study, compared to 18 patients in the eplerenone group (33%).

Conclusively, Half-dose PDT is superior to oral eplerenone for cCSC with respect to both short-term safety and efficacy outcomes.

Source: https://www.ajo.com/article/S0002-9394(21)00345-7/fulltext?rss=yes